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(P.-H. Liang).Picornaviruses (PV) and coronaviruses (CoV) are positive-stranded RNA viruses which infect mil-
lions of people worldwide each year, resulting in a wide range of clinical outcomes. As reported
in this study, using high throughput screening against 6800 small molecules, we have identiﬁed
several novel inhibitors of SARS-CoV 3CLpro with IC50 of low lM. Interestingly, one of them equally
inhibited both 3Cpro and 3CLpro from PV and CoV, respectively. Using computer modeling, the struc-
tural features of these compounds as individual and common protease inhibitors were elucidated to
enhance our knowledge for developing anti-viral agents against PV and CoV.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Picornaviruses (PV) are small nonenveloped RNA viruses with a
single strand of genomic RNA of 7500–8000 nucleotides [1]. The
members of PV include rhinoviruses (RV), enteroviruses (EV), cox-
sackieviruses (CV), polioviruses, echoviruses, encephalomyocard-
itis viruses, meningitis virus, foot and mouth viruses, hepatitis A
virus, and so on. Among them, RV is the major cause of the com-
mon cold, whereas EV and CV infection can cause hand, foot, and
mouth diseases in human and animals. In severe cases, EV can
damage the central nervous systems leading to viral meningitis,
encephalitis, and severe myocarditis, as well as fatal pulmonary
edema [2–5]. CV strain B is a major human pathogen that causes
meningitis and mycocarditis leading to heart failure in young
adults and congestive heart failure [6]. In these PV, a chymotryp-
sin-like protease (named 3Cpro) is required to process polyproteins
into mature proteins for viral replication, which represents a prom-
ising anti-viral drug target [7].chemical Societies. Published by E
logical Chemistry, Academia
9759.
, phliang@gate.sinica.edu.twOn the other hand, coronaviruses (CoV) are the positive-
stranded RNA viruses with larger genome of 27–32 kb, which
typically cause respiratory and enteric diseases, pneumonia,
exacerbation of asthma, neurological symptoms, and myocarditis
in humans and domestic animals. An outbreak of severe acute
respiratory syndrome (SARS), caused by a novel human CoV, was
spread from China to 29 countries in 2003, infecting a total of
8000 people and killing 800 patients [8]. SARS-CoV contains a
3C-like protease (3CLpro) analogous to the 3Cpro of PV, responsible
for processing two overlapping polyproteins, pp1a (486 kDa) and
pp1ab (790 kDa). Other members of human CoV including CoV-
229E, CoV-OC43, CoV-HKU1, and CoV-NL63 also require a 3CLpro
in the maturation of viral proteins.
Several inhibitors have been developed to inhibit the 3Cpro of RV
and EV [9–12] and 3CLpro of SARS-CoV [13–15]. However, their
inhibitors can not be mutually used without modiﬁcation. For
example, AG7088, a potent inhibitor of RV and other picornaviral
3Cpro [16], failed to inhibit SARS-CoV 3CLpro [17]. Unlike the 3CLpro,
which is dimeric and in which each subunit is composed of three
domains, the 3Cpro is a monomer with only the two catalytic
domains. The structure-based sequence alignment (Fig. 1) shows
some sequence differences, which may alter inhibitor speciﬁcity.
In this study, we performed high throughput screening using a li-
brary of 6800 compounds to ﬁnd ﬁve novel inhibitors of thelsevier B.V. All rights reserved.
550 C.-J. Kuo et al. / FEBS Letters 583 (2009) 549–555SARS-CoV 3CLpro, 4 of which also inhibited another human CoV-
229E 3CLpro, but did not inhibit the 3Cpro from RV14, CVB3, and
EV71. But, one compound was found to almost equally inhibit
these 3CLpro and 3Cpro. From computer modeling, we rationalized
the binding discrepancy of the inhibitors against these proteases.
The information is useful to further developmore potent individual
or common inhibitors of 3Cpro and 3CLpro of PV and CoV for anti-
viral drug discovery.
2. Methods
2.1. Expression and puriﬁcation of the proteases
Two types of proteases including 3CLpro from SARS-CoV and
CoV-229E and 3Cpro from CVB3, EV71, and RV14 were used to assay
the inhibitors in this study. The SARS-CoV 3CLpro and EV71 3Cpro
were prepared as reported previously [12,18]. For expressing
CVB3, RV14, and CoV-229E proteases, the genes were cloned from
viral cDNAs by using polymerase chain reaction (PCR) as reported
elsewhere.Fig. 1. A structure-based sequence alignment of SARS-CoV 3CLpro, CoV-229E 3CLpro, CVB3
the sequence and the secondary elements according to the 3Cpro structure are shown bel
3Cpro, and Glu (only for 3Cpro).2.2. Primary screening
For screening, 0.05 lM SARS 3CLpro, 6 lM ﬂuorogenic substrate
Dabcyl-KTSAVLQSGFRKME-Edans, and 50 lM of approximately
6800 compounds provided by Korea Chemical Bank (Daejeon, Kor-
ea) were used. Enhanced ﬂuorescence of the reactions in the buffer
of 20 mM Bis-Tris at pH 7.0 was monitored at 538 nm with excita-
tion at 355 nm using a ﬂuorescence plate reader. The compounds
which inhibited more than 50% of the protease activity at 50 lM
were selected for the next assay run at 10 lM.
2.3. IC50 determination
The ﬁve hits that inhibited SARS-CoV 3CLpro at 10 lM were also
evaluated against CoV-229E 3CLpro, EV71 3Cpro, CVB3 3Cpro, and
RV14 3Cpro. In the assay solution, the activities of these proteases
(0.5 lM) with 10 lM ﬂuorogenic substrate in the buffers of
10 mM MES at pH 6.5 and 6.0 (the optimal pH for EV71 and
RV14 proteases, respectively) and 10 mM HEPES at pH 7.5 (for
CoV-229E and CVB3 proteases) were measured in the presence3Cpro, EV71 3Cpro, and RV14 3Cpro. The domains according to 3CLpro are shown above
ow it. Arrows indicate the essential catalytic amino acids His and Cys for 3CLpro and
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values.
2.4. Computer modeling of the inhibitors binding with the proteases
For the modeling analysis, we used the crystal structure of SARS
3CLpro in complex with a peptide inhibitor (PDB code 1UK4) [19],
the structures of CoV-229E 3CLpro and CVB3 3Cpro solved by us,
and the structural model of EV71 3Cpro constructed from the struc-
ture of RV 3Cpro (PDB code 1CQQ) [20]. Docking process was per-
formed using an automated ligand-docking subprogram of the
Discovery Studio Modeling 1.2 SBD (Accelrys Inc., San Diego, CA),
with a set of parameters chosen to control the precise operation
of the genetic algorithm. Docking runs were carried out using stan-
dard default settings ‘‘grid resolution” of 5 Å, ‘‘site opening” ofFig. 2. Dose–response curves for the ﬁve hits against SARS-CoV 3CLpro from the screeni
7.2 ± 0.7 lM (21155), (B) 10.6 ± 1.3 lM (22723), (C) 7.0 ± 0.8 lM (27548), (D) 3.3 ± 0.2
inhibitors are summarized in Table 1.12 Å, and ‘‘binding site” selected for deﬁning the active site
cavity.
3. Results
3.1. Screening of the protease inhibitors
We ﬁrst screened against a library of 6800 compounds for
inhibiting SARS-CoV 3CLpro. From the primary screening, there
were 66 compounds which showed more than 50% inhibition of
the enzyme activity at 50 lM. We further tested their inhibitory
activities at 10 lM and ﬁve of them (21155, 22723, 27548,
43146, and 48511) showed IC50 values smaller than 10 lM.
According to their dose–response curves as shown in Fig. 2A–E,
the ﬁve hits 21155, 22723, 27548, 43146, and 48511 displayedng. IC50 values were determined from the curves using equation 1. These were (A)
lM (48511), and (E) 8.1 ± 0.9 lM (43146). The structures and activities of these
Table 1
Summary of IC50 values (lM) of the ﬁve hits with SARS-CoV 3CLpro, and other 3C(L) proteases.
Compound ID Structure SARS 3CL 229E 3CL CVB3 3C EV71 3C RV14 3C
21155 S
N
S
O
N
O
O
O
CH3
7.2 ± 0.7 5.6 ± 1.0 >50 >50 >50
22723
N
N
S
N
N
N O
OHCl
Cl
OH
10.6 ± 1.3 12.4 ± 0.8 >50 >50 >50
27548 N
OO
7.0 ± 0.8 6.6 ± 0.3 >50 >50 >50
48511
N
O
O
N
O
O
3.3 ± 0.2 1.8 ± 0.7 >50 >50 >50
43146
N
N
N
N
N 8.1 ± 0.9 10.3 ± 1.1 5.4 ± 0.2 3.3 ± 0.3 5.2 ± 0.6
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8.1 ± 0.9 lM, respectively, against the SARS 3CLpro. Similar
inhibition results were observed for 3CLpro of CoV-229E (data sum-
marized in Table 1), but not for 3Cpro. However, 43146 inhibited
both 3Cpro and 3CLpro with IC50 values of 10.3 ± 1.1 lM, 5.4 ±
0.2 lM, 3.3 ± 0.3, and 5.2 ± 0.6 lM, respectively, against CoV-
229E 3CLpro, CVB3 3Cpro, EV71 3Cpro and RV14 3Cpro (Fig. 3A–D
and summarized in Table 1). This compound contains a dihydropy-
razole ring with three substituents, two phenyl groups and a
lengthy N-butyl-benzimidazolylamino-toluene.
3.2. Inhibition potencies of the 43146 analogues
Since 43146 inhibited 3CLpro and 3Cpro, its analogues including
45240, 68638, 55688, and 55585 obtained from another compound
library were evaluated. As shown in Table 2, all of them showed
good potencies against the ﬁve proteases. The most potent
compound was 45240, and its IC50 values in inhibiting the 3C(L)
proteases were measured to be 2.5 ± 0.2 lM (SARS-CoV 3CLpro),
2.6 ± 0.4 lM (CoV-229E 3CLpro), 1.2 ± 0.3 lM (CVB3 3Cpro), 0.5 ±
0.1 lM (EV71 3Cpro), and 1.7 ± 0.1 lM (RV14 3Cpro) (Table 2). This
compound contains four rings, three phenyl groups and one imid-
azole, surrounding a central dihydropyrazole ring, without the
lengthy side chain as seen in 43146. Compound 68638 with ben-
zylcyclohexane ring fused with the dihydropyrazole ring and acet-
yl and iodobenzyl groups attached to the central ring showed less
inhibition against both 3Cpro and 3CLpro (Table 2). The other two
compounds, 55688 and 55585, with shorter side chains attachedto the benzimidazolyl group showed similar inhibitory activities
as compared to 43146 (Table 2).
3.3. Computer modeling of 21155, 22723, 27548, and 48511 binding to
the proteases
These inhibitors are competitive inhibitors with respect to the
substrate (data not shown), indicating they bind in the active site.
To rationalize the binding discrepancy of these inhibitors against
these proteases, their binding modes with SARS-CoV 3CLpro and
four other proteases were modeled and some of them are shown
in Fig. 4. The ﬁrst four inhibitors of SARS-CoV 3CLpro are more rigid
because the thiazolopyridine in 21155, the dichlorobenzoquinoli-
none in 22723, the isoindoledione in 27548, and the oxazole in
48511 adopt planar structures and the three substituents of the
oxazole ring in 48511 are ﬁxed in a conformer, due to the 1,2-steric
interaction between the acetate group and the N-aryl imino group
as well as the biaryl interaction between the phenyl and oxazole to
prohibit their free rotation. All these compounds can be considered
as two rigid aromatic moieties connected by a small linker. Based
on the computer modeling, each of these aromatic moieties is
bound to S1 or S2 site of SARS protease by forming H-bonds and
hydrophobic interactions (Fig. 4A–D). As shown in the computer
modeling, Glu166 side chain of SARS 3CLpro forms H-bonds with
these four inhibitors. However, the corresponding amino acid res-
idue in 3Cpro is Gly164, which lacks the side chain to form H-bond
with any of these compounds (also see Fig. 4F), leading to loss of
inhibition. In addition, the 3Cpro have more open but shallow S2
Table 2
IC50 values (lM) of compound 43146 analogs with SARS-CoV 3CLpro, and other 3C(L) proteases.
Compound ID Structure SARS 3CL 229E 3CL CVB3 3C EV71 3C RV14 3C
45240 NN
N
N
Cl Cl
Cl
Br
2.5 ± 0.2 2.6 ± 0.4 1.2 ± 0.3 0.5 ± 0.1 1.7 ± 0.1
68638
NN
O
IO
CH3
CH3
9.8 ± 0.8 12.4 ± 0.8 7.0 ± 0.8 10.6 ± 1.3 5.3 ± 1.1
55688
NN
N
NN
CH3
8.0 ± 0.5 9.6 ± 0.3 6.1 ± 0.5 8.5 ± 0.6 7.7 ± 1.0
55585
NN
N
NN
CH3 8.4 ± 0.2 10.2 ± 0.7 6.5 ± 0.6 4.7 ± 0.2 6.4 ± 0.3
Fig. 3. Dose–response curves for 43146 against 229E 3CLpro, CVB3 3Cpro, EV71 3Cpro and RV14 3Cpro. IC50 values were determined from the curves using equation 1. These
were (A) 10.3 ± 1.1 lM (229E 3CLpro), (B) 5.4 ± 0.2 lM (CVB3 3Cpro), (C) 3.3 ± 0.3 lM (EV71 3Cpro), and (D) 5.2 ± 0.6 lM (RV14 3Cpro).
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Fig. 4. Computer modeling of the binding modes of the inhibitors in the active site of the SARS 3CLpro. The more rigid moieties of the inhibitors 21155, 22723, 27548, 48511
are probably bound to S1 and S2 sites as shown in (A), (B), (C), and (D), respectively. (E) 43146 binds SARS-CoV 3CLpro differently with the biphenyl 4,5-dihydro-1H-pyrazole
moiety anchored at the S1’ and S2 sites and the rest of the molecule at the S3 and the following sites. The hydrogen bond interactions were represented by yellow dotted lines.
554 C.-J. Kuo et al. / FEBS Letters 583 (2009) 549–555site (due to its partial blockage by Leu127) than 3CLpro according to
the crystal structures of RV 3Cpro [20] and CVB3 3Cpro (Lee et al.,
unpublished results) compared to 3CLpro (also see Fig. 4F). Thus,
3Cpro can not hold these compounds tightly.3.4. Binding modes of 43146 and its analogues to the proteases
In contrast, the compound 43146 is more ﬂexible, because the
dihydropyrazole is not planar, and the phenyl group is linked to
C.-J. Kuo et al. / FEBS Letters 583 (2009) 549–555 555the sp3-hybridized carbon of the dihydropyrazole ring, so it is free
for rotation. Different from the binding modes of the other 4 inhib-
itors, the diphenyl 4,5-dihydro-1H-pyrazole moiety of 43146 ﬁts
well at the S10 and S2 sites in the SARS 3CLpro (Fig. 4E) with the rest
of the molecule at the S3 site and beyond. With this binding mode,
the compound was predicted to also bind well in the 3Cpro, consis-
tent with the inhibition data. In fact, RV 3Cpro prefers a phenyl
group at the S2 site as evidenced by its strong inhibition by
AG7088 which has a P2-ﬂuorophenylalanine. Thus, it could be
rationalized by computer modeling that only 43146 among the ﬁve
hits can inhibit the three 3Cpro in addition to the 3CLpro.
The analogues of 43146, including 45240, 68638, 55688, and
55585, bind in the 3Cpro and 3CLpro active sites with similar modes
to that of 43146 (data not shown). Compared to 43146, 55688 and
55585 only have minor structural difference with shorter alkyl
groups attached to the benzimidazole ring, so that they showed
similar inhibition against the proteases. The fused ring system
and the phenyl group in 68638 may also span from S10 to S2 sites
in both kinds of proteases, yielding similar inhibition. However,
45240 showed a signiﬁcantly better inhibition against the 3Cpro
than 43146. Apparently, the lengthy side chain attached to the
phenyl group in the compound did not provide additional interac-
tion with the protease, consistent with the binding mode shown in
Fig. 4E. However, the additional interaction is provided by the pyr-
idine ring bound near the more open S10 site in 3Cpro.4. Discussion
AG7088 is the best inhibitor identiﬁed so far for 3Cpro, which
not only inhibits the 3Cpro from RV, but also those from CV and
EV [16]. However, it did not inhibit 3CLpro from SARS-CoV [17]. This
may be partially due to the blockage of its P1-lactam ring by the
relatively larger Glu166 side chain and also the S2 site of 3CLpro
is narrower although it is deeper. Therefore, when the P2-phenyl-
alanine is changed to non-planar leucine or cyclohexane without
changing the P1-lactam, they became good inhibitors of SARS
3CLpro [21]. Unlike AG7088, which is a ketomethyl isostere of a
tripeptide-conjugated ester, compound 43146 is not peptide-
like. From the random screening as shown in the study, we have
found a starting point toward the development of non-peptide
multiple-function inhibitors against CoV and PV. With further
modiﬁcation of these individual and common inhibitors of the viral
proteases, we hope to ﬁnd solution for the possible reoccurrence of
SARS and other diseases caused by the viruses with the 3Cpro and
3CLpro.Acknowledgements
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